Knight Therapeutics Inc (TSE:GUD) had its price target lifted by research analysts at Scotiabank from C$10.50 to C$11.00 in a research note issued to investors on Friday. The brokerage currently has an “outperform” rating on the stock. Scotiabank’s price target would suggest a potential upside of 8.91% from the company’s previous close.

A number of other equities analysts have also recently commented on the stock. National Bank Financial boosted their price target on shares of Knight Therapeutics from C$11.00 to C$11.75 in a research note on Wednesday, March 15th. TD Securities reissued a “buy” rating and issued a C$12.50 price target on shares of Knight Therapeutics in a research note on Tuesday, March 14th. CIBC cut their price target on shares of Knight Therapeutics from C$13.00 to C$9.80 in a research note on Friday, January 13th. Finally, Mackie cut shares of Knight Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from C$12.00 to C$10.75 in a research note on Wednesday, January 4th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of C$11.16.

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Shares of Knight Therapeutics (TSE:GUD) opened at 10.10 on Friday. The stock’s 50 day moving average is $10.56 and its 200 day moving average is $9.93. The firm has a market capitalization of $1.34 billion and a PE ratio of 71.13. Knight Therapeutics has a 52-week low of $7.20 and a 52-week high of $11.03.

Your IP Address:

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.